Growth hormone secretagogue receptor (GHSR) agonists like GHRP-2 are well known for their ability to produce large spikes in GH levels. These spikes, while providing a number of interesting and important benefits in animal models, are also short-lived because the half-life of most GHSR agonists is relatively short. To achieve long-term GH level increases, it is possible to use a GHRH analogue like modified GRF. This provides a long-term increase in both basal and peak GH levels, but nowhere near the kind of GH spike that a GHSR agonists provides. In addition, animal models show that GHRH analogues are susceptible to somatostatin interference, which can offset increases in GH levels.
Add your review
Your email address will not be published. Required fields are marked *
Please login to write review!
Looks like there are no reviews yet.